Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

"Today, Adamas announces FDA approval of an extended release amantadine capsule called GOCOVRI. This drug will provide a practical once a day solution for dyskinesia management and reducing "off" time. Patients who are currently well managed using multiple doses per day of generic amantadine for dyskinesia will not likely derive additional symptomatic benefits from switching to once a day dosing; however, patients experiencing side effects from amantadine may wish to discuss options with their neurologist.

Both GOCOVRI and generic amantadine use is linked to a risk of side effects such as dizziness, hallucinations or blotching on the skin of the legs.  If you are considering starting this medicine or switching to this medicine we recommend consulting with your doctor.

In an independent Parkinson's Foundation study prior to this approval, we found that generic amantadine use improved dyskinesia in patients.  However, amantadine use does have a risk of side effects including insomnia and hallucinations. GOCORVI has been designed to limit the risk of these complications and it will not carry generic amantadine's warning for insomnia."

Call our Helpline, 1-800-4PD-INFO, or visit www.GOCOVRI.com for more information.

About the Parkinson's Foundation

The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).

About Parkinson's Disease (PD)

Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

# # #

Friday, August 25, 2017
National Parkinson Foundation Hosts Caregiver Summit
Monday, September 12, 2016

MIAMI — The National Parkinson Foundation (NPF), a division of the Parkinson’s Foundation, will be hosting the first-ever Caregiver Summit, geared specifically toward caregivers of people living with Parkinson’s disease (PD).

Refuting Claims Regarding Presidential Nominee Hillary Clinton and Parkinson’s Disease
Friday, September 9, 2016

The National Parkinson Foundation has received several questions about whether Hillary Clinton has Parkinson's disease (PD).

The allegations that Hillary Clinton suffers from Parkinson's disease have been reviewed by NPF's National Medical Director, Michael S. Okun, MD, and by others from NPF's Centers of Excellence network and been unanimously dismissed by every Parkinson's expert who has weighed in.

Parkinson's Disease Foundation Invests in Next Generation of Physical Therapy Leaders
Thursday, August 4, 2016

PDF Launches Innovative Pilot Training Program for Physical Therapy Educators

The Parkinson's Disease Foundation® (PDF®) is pleased to announce the launch of the Physical Therapy Faculty Program to improve care for the nearly one million people in the United States living with Parkinson’s disease. The pilot program launched this week in Boston, MA.

National Parkinson Foundation (NPF) and the Parkinson’s Disease Foundation (PDF) Complete Merger to Form the Parkinson’s Foundation
Monday, August 1, 2016

New York and Miami, August 1, 2016—The Boards of Directors of the National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF) announced today that they have finalized the merger of the two non-profit organizations. The organization will operate as the Parkinson's Foundation with offices in New York City and Miami.

Parkinson’s Disease Foundation Opens $500,000 in Grant Funding, Urges Scientists to Address Key Unmet Needs in Patient Community
Thursday, July 21, 2016

New Awards Fund Translational Patient-Driven Research Projects

Parkinson's Disease Foundation Invests in Next Generation of Patient Leaders
Friday, July 15, 2016

The Parkinson's Disease Foundation® (PDF®) is pleased to welcome 20 people with Parkinson's disease and care partners to its national research advocacy network. These individuals join more than 325 patient leaders who are helping PDF solve, treat and end Parkinson's disease.

The National Parkinson Foundation’s Moving Day® Walks Fund Parkinson’s Programs in Six Cities
Monday, June 27, 2016

MIAMI — The National Parkinson Foundation (NPF) is proud to announce that the 2015 fall walk season of Moving Day®, A Walk for Parkinson’s, has funded nearly $300,000 in mission services to make life better for people living with Parkinson’s and their caregivers in six communities.

NPF and Global Kinetics Corporation Announce the Commencement of a Clinical Trial to Study Impact of Personal KinetiGraph Use in Routine Clinical Care of Patients with Parkinson's Disease
Wednesday, June 22, 2016

A multi-center, randomized controlled trial to assess whether the use of continuous objective measurement of changes in mobility in patients with Parkinson’s disease can improve physician treatment decisions and patient outcomes.

The National Parkinson Foundation Partners with Honor to Help the Home Care Company Deliver Personalized Care in the Home
Tuesday, June 21, 2016

The National Parkinson Foundation (NPF) and Honor home care announced today a collaborative partnership to bring personalized care in the home to people diagnosed with Parkinson’s.  Honor will license the NPF’s proprietary care guidance.

The National Parkinson Foundation Announces New Findings from Largest-Ever Parkinson’s Study of 8,000 Patients Worldwide
Monday, June 20, 2016

Latest Data Point To Improve Patient Care Through Precision Treatment

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.